Gritstone - Model EDGE - Cancer Cell Therapies
From Our Pipeline
We are leveraging EDGE to define targets for T-cell receptor (TCR) directed cell therapies. These additional targets that were identified and validated by Gritstone EDGE™ enable us to partner with others or develop additional therapeutic approaches to redirect T cells onto tumors using these highly specific targets.
-
Most popular related searches
Products Details
We have a collaboration with bluebird bio to identify tumor-specific targets and natural TCRs directed to those targets for use in bluebird bio’s established cell therapy platforms. bluebird bio will conduct all development, manufacturing and commercial activities. Gritstone will provide 10 tumor-specific targets across several tumor types and, in certain cases, TCRs directed to those targets to bluebird bio.
Customer reviews
No reviews were found for Gritstone - Model EDGE - Cancer Cell Therapies. Be the first to review!